Sequential delivery of eosinophil cationic protein and interleukin-4 enhances their therapeutic efficacy for myocardial infarction

Eosinophils protect heart from post-myocardial infarction (MI) injury via cationic protein (ECP) and interleukin-4 (IL-4). Here we engineered and optimized a cell-free therapy for MI via regulated delivery of ECP and IL-4. Pluronic F127 thermosensitive hydrogels embedded with gelatin methacryloyl microspheres (GMs) were constructed for sequential ECP and IL-4 delivery. Immediately following MI, mice received an intrapericardial injection of therapeutic formulations. At 3 days post-MI, codelivery of ECP and IL-4 limited infarct size and preserved cardiac function. Rapid ECP release followed by sustained IL-4 release (IL-4@GM + ECP) yielded the most favorable outcomes with attenuated cardiomyocyte apoptosis and enhanced M2 macrophage contents in post-MI hearts. At 28 days post-MI, IL-4@GM + ECP exhibited robust cardiac functional recovery and cardiac geometry maintenance with minimal fibrotic scarring. Microfil perfusion imaging revealed that IL-4@GM + ECP enhanced angiogenesis with abundant perfused neovessels in the infarcts. Matrigel plug assays confirmed that codelivery of ECP and IL-4 yielded mature and tight vessel structures with CD31 + endothelial cell (EC) lumens surrounded by α-SMA + smooth muscle cells (SMCs) and PDGFR-β + pericytes. Mechanistic studies demonstrated that ECP induced angiogenesis by enhancing EC proliferation, migration, and cellular junctions. Conversely, IL-4 disrupted endothelial junctions but enhanced SMC migration to stabilize nascent endothelium. Sequential delivery of ECP and IL-4 helps generate functional neovessels. The therapeutic efficacy of IL-4@GM + ECP in MI was validated in eosinophil-deficient ΔdblGATA mice. In summary, rapid ECP release, followed by sustained IL-4 release effectively improved cardiac function post-MI by orchestrating neovessel formation, providing a cell-free alternative to eosinophil-based cell therapy for MI.

Authors

Institutions

Publication Details

Journal
Bioactive Materials
Published
2026-11-18
DOI
https://doi.org/10.1016/j.bioactmat.2026.08.054
Primary Topic
Cardiac Fibrosis and Remodeling
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sequential delivery of eosinophil cationic protein and interleukin-4 enhances their therapeutic efficacy for myocardial infarction

Guangbo Ji, Qiang Zhao, Yushu Chu, Guo-Ping Shi et al.
Bioactive Materials
Cardiac Fibrosis and Remodeling
article

Sequential delivery of eosinophil cationic protein and interleukin-4 enhances their therapeutic efficacy for myocardial infarction

Guangbo Ji, Qiang Zhao, Yushu Chu, Guo-Ping Shi, Zhixin Xu, Jia Li, 吳亭恩, Guoxiang Zhao, Junli Guo, Meng Qian, Jinwei Tian, Yan Chen, Tongyao Li, Yamin Zhang, Yating Mu
article en

Abstract

Eosinophils protect heart from post-myocardial infarction (MI) injury via cationic protein (ECP) and interleukin-4 (IL-4). Here we engineered and optimized a cell-free therapy for MI via regulated delivery of ECP and IL-4. Pluronic F127 thermosensitive hydrogels embedded with gelatin methacryloyl microspheres (GMs) were constructed for sequential ECP and IL-4 delivery. Immediately following MI, mice received an intrapericardial injection of therapeutic formulations. At 3 days post-MI, codelivery of ECP and IL-4 limited infarct size and preserved cardiac function. Rapid ECP release followed by sustained IL-4 release (IL-4@GM + ECP) yielded the most favorable outcomes with attenuated cardiomyocyte apoptosis and enhanced M2 macrophage contents in post-MI hearts. At 28 days post-MI, IL-4@GM + ECP exhibited robust cardiac functional recovery and cardiac geometry maintenance with minimal fibrotic scarring. Microfil perfusion imaging revealed that IL-4@GM + ECP enhanced angiogenesis with abundant perfused neovessels in the infarcts. Matrigel plug assays confirmed that codelivery of ECP and IL-4 yielded mature and tight vessel structures with CD31 + endothelial cell (EC) lumens surrounded by α-SMA + smooth muscle cells (SMCs) and PDGFR-β + pericytes. Mechanistic studies demonstrated that ECP induced angiogenesis by enhancing EC proliferation, migration, and cellular junctions. Conversely, IL-4 disrupted endothelial junctions but enhanced SMC migration to stabilize nascent endothelium. Sequential delivery of ECP and IL-4 helps generate functional neovessels. The therapeutic efficacy of IL-4@GM + ECP in MI was validated in eosinophil-deficient ΔdblGATA mice. In summary, rapid ECP release, followed by sustained IL-4 release effectively improved cardiac function post-MI by orchestrating neovessel formation, providing a cell-free alternative to eosinophil-based cell therapy for MI.

Bioactive MaterialsVol. 70
Harbin Medical University (CN), Peking University (CN), Nankai University (CN), Tianjin First Center Hospital (CN), Zhongda Hospital Southeast University (CN), Second Affiliated Hospital of Harbin Medical University (CN), State Key Laboratory of Medicinal Chemical Biology (CN), Tianjin Medical University (CN), Southeast University (CN), Hainan Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, Natural Science Foundation of Tianjin City
Good health and well-being
Cardiac Fibrosis and Remodeling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon